FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2183618944> ?p ?o ?g. }

• W2183618944 endingPage "197" @default.
• W2183618944 startingPage "189" @default.
• W2183618944 abstract "This phase-2b study examined the safety and efficacy of an all-oral, interferon-free combination of the NS5A replication complex inhibitor daclatasvir (DCV), the NS3 protease inhibitor asunaprevir (ASV), and the nonnucleoside NS5B polymerase inhibitor beclabuvir (BCV) with or without ribavirin in patients with HCV genotype (GT) 1 infection.A total of 187 patients received 12 weeks of DCV 30 mg BID plus ASV 200 mg BID and BCV 150 mg BID (n = 86) or 75 mg BID with (n = 21) or without (n = 80) weight-based ribavirin BID. The primary endpoint was HCV RNA <25 IU/ml at post-treatment week 12 (SVR12).Overall, 90% of patients (169/187) in the combined treatment groups achieved SVR on or after post-treatment week 12. SVR rates were similar across subgroups (by mITT analysis), i.e. patients with cirrhosis (88%, 14/16), HCV GT-1a (90%, 137/155), and IL28B non-CC genotype (90%, 115/128). There were no drug-related serious AEs or grade 4 AEs. The most frequently reported AEs were headache, diarrhoea, fatigue and nausea. Addition of ribavirin to DCV+ASV+BCV was associated with decreased haemoglobin, compared with DCV+ASV+BCV alone. There were six grade 3/4 laboratory abnormalities noted, all unrelated to the study drugs. Viral breakthrough occurred in 2.5-4.8% of patients across groups and appeared unrelated to BCV dose or ribavirin inclusion.Results support phase 3 evaluation of a twice-daily, fixed-dose formulation of this DCV+ASV+BCV regimen with or without ribavirin in HCV GT-1-infected patients." @default.
• W2183618944 created "2016-06-24" @default.
• W2183618944 creator A5011922070 @default.
• W2183618944 creator A5014497373 @default.
• W2183618944 creator A5017159867 @default.
• W2183618944 creator A5017942355 @default.
• W2183618944 creator A5020419303 @default.
• W2183618944 creator A5020674512 @default.
• W2183618944 creator A5026282992 @default.
• W2183618944 creator A5039696464 @default.
• W2183618944 creator A5039815889 @default.
• W2183618944 creator A5054070286 @default.
• W2183618944 creator A5054722909 @default.
• W2183618944 creator A5056557259 @default.
• W2183618944 creator A5059337045 @default.
• W2183618944 creator A5065814121 @default.
• W2183618944 creator A5068290058 @default.
• W2183618944 creator A5075322332 @default.
• W2183618944 creator A5080386622 @default.
• W2183618944 creator A5082856467 @default.
• W2183618944 creator A5087714251 @default.
• W2183618944 creator A5091503748 @default.
• W2183618944 date "2015-12-06" @default.
• W2183618944 modified "2023-10-18" @default.
• W2183618944 title "Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients" @default.
• W2183618944 cites W1510051491 @default.
• W2183618944 cites W1804925654 @default.
• W2183618944 cites W1831899697 @default.
• W2183618944 cites W1963756548 @default.
• W2183618944 cites W1972821220 @default.
• W2183618944 cites W1980771473 @default.
• W2183618944 cites W1981385281 @default.
• W2183618944 cites W1995591620 @default.
• W2183618944 cites W1997249384 @default.
• W2183618944 cites W2060779536 @default.
• W2183618944 cites W2078251659 @default.
• W2183618944 cites W2084798867 @default.
• W2183618944 cites W2092646281 @default.
• W2183618944 cites W2113428683 @default.
• W2183618944 cites W2124151787 @default.
• W2183618944 cites W2125958583 @default.
• W2183618944 cites W2125963799 @default.
• W2183618944 cites W2143244227 @default.
• W2183618944 cites W2143559032 @default.
• W2183618944 cites W2147822795 @default.
• W2183618944 cites W2158761079 @default.
• W2183618944 cites W2166962970 @default.
• W2183618944 cites W2167407662 @default.
• W2183618944 cites W4211051574 @default.
• W2183618944 doi "https://doi.org/10.1111/liv.12964" @default.
• W2183618944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26473667" @default.
• W2183618944 hasPublicationYear "2015" @default.
• W2183618944 type Work @default.
• W2183618944 sameAs 2183618944 @default.
• W2183618944 citedByCount "23" @default.
• W2183618944 countsByYear W21836189442016 @default.
• W2183618944 countsByYear W21836189442017 @default.
• W2183618944 countsByYear W21836189442018 @default.
• W2183618944 countsByYear W21836189442019 @default.
• W2183618944 countsByYear W21836189442020 @default.
• W2183618944 countsByYear W21836189442021 @default.
• W2183618944 countsByYear W21836189442023 @default.
• W2183618944 crossrefType "journal-article" @default.
• W2183618944 hasAuthorship W2183618944A5011922070 @default.
• W2183618944 hasAuthorship W2183618944A5014497373 @default.
• W2183618944 hasAuthorship W2183618944A5017159867 @default.
• W2183618944 hasAuthorship W2183618944A5017942355 @default.
• W2183618944 hasAuthorship W2183618944A5020419303 @default.
• W2183618944 hasAuthorship W2183618944A5020674512 @default.
• W2183618944 hasAuthorship W2183618944A5026282992 @default.
• W2183618944 hasAuthorship W2183618944A5039696464 @default.
• W2183618944 hasAuthorship W2183618944A5039815889 @default.
• W2183618944 hasAuthorship W2183618944A5054070286 @default.
• W2183618944 hasAuthorship W2183618944A5054722909 @default.
• W2183618944 hasAuthorship W2183618944A5056557259 @default.
• W2183618944 hasAuthorship W2183618944A5059337045 @default.
• W2183618944 hasAuthorship W2183618944A5065814121 @default.
• W2183618944 hasAuthorship W2183618944A5068290058 @default.
• W2183618944 hasAuthorship W2183618944A5075322332 @default.
• W2183618944 hasAuthorship W2183618944A5080386622 @default.
• W2183618944 hasAuthorship W2183618944A5082856467 @default.
• W2183618944 hasAuthorship W2183618944A5087714251 @default.
• W2183618944 hasAuthorship W2183618944A5091503748 @default.
• W2183618944 hasConcept C126322002 @default.
• W2183618944 hasConcept C159047783 @default.
• W2183618944 hasConcept C2522874641 @default.
• W2183618944 hasConcept C2776408679 @default.
• W2183618944 hasConcept C2776979040 @default.
• W2183618944 hasConcept C2777103181 @default.
• W2183618944 hasConcept C2778390639 @default.
• W2183618944 hasConcept C2778986448 @default.
• W2183618944 hasConcept C2780040827 @default.
• W2183618944 hasConcept C2780580376 @default.
• W2183618944 hasConcept C2781413609 @default.
• W2183618944 hasConcept C2781463415 @default.
• W2183618944 hasConcept C71924100 @default.
• W2183618944 hasConcept C90924648 @default.
• W2183618944 hasConceptScore W2183618944C126322002 @default.

• next